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Tiivistelmä
Rintasyöpä  on  yleinen,  usein  kuolemaan  johtava  sairaus,  mistä  johtuen  sitä  on  tutkittu
runsaasti viimeisten vuosikymmenten aikana. Laajamittaisen tutkimustyön ansiosta lukuisia
rintasyövän  syntyyn  ja  kehitykseen  vaikuttavia  solu-  ja  molekyylitason  mekanismeja  on
onnistuttu selvittämään. Nykyään tunnetaan myös monia rintasyövän alatyyppejä, joista yksi
tutkituimmista on HER-2 -proteiinia tavallista enemmän tuottava HER-2 -positiivinen muoto.
HER-2 -positiivisen  rintasyövän  hoitoon on kehitetty  useita  lääkkeitä,  joista  käytetyin  on
monoklonaalinen  vasta-aine  trastutsumabi,  joka  tarttuu  HER-2  -proteiiniin  ja  estää  sen
toimintaa.  On  kuitenkin  havaittu,  että  HER-2  -reseptoriin  kohdennetut,  ligandista
riippumatonta signalointia estävät lääkkeet, kuten edellä mainittu trastutsumabi, eivät tehoa
kaikkiin  HER-2  -positiivisiin  kasvaimiin.  Tästä  johtuen  uusia  lääkekohteita  on  pyritty
etsimään tehokkaampien lääkkeiden kehittämiseksi.  Yksi lupaava kohde on HER-2/HER-3
-dimeeri,  joka  aktivoi  apoptoosia  estäviä  sekä  solujen  kasvua  ja  jakaantumista  edistäviä
signalointireittejä.
Tämän  opinnäytetyön  tavoitteina  oli  määrittää  HER-2/HER-3  -dimeerien  määrä
kahdessatoista  rintasyöpä-  ja  yhdessä  mahasyöpäsolulinjassa  proximity  ligation  assay
-tekniikkaa käyttäen, tutkia vaikuttavatko HER-3 -pistemutaatiot dimeerien muodostumiseen
ja solujen lääkeherkkyyteen sekä määrittää näiden pistemutaatioiden yleisyys rintasyövässä.
HER-2/HER-3  -dimeereitä  oli  selvästi  eniten  voimakkaasti  HER-2  -positiivisissa
solulinjoissa,  kun  taas  HER-2  -negatiivisissa  solulinjoissa  dimeereitä  oli  vain  muutamia.
Lisäksi havaittiin odotetusti,  että pertutsumabi, HER-2/HER-3 -dimerisaatiota estävä lääke,
vähensi dimeerien määrää useimmissa solulinjoissa. In vitro -lääkeherkkyyskokeet osoittivat,
että  dimerisaation  estämisen  lisäksi pertutsumabi  heikensi  solujen  elinkelpoisuutta
suurimmassa osassa HER-2 -positiivisia solulinjoja. HER-2 -positiivisten SK-BR-3 -solujen
elinkelpoisuuten pertutsumabilla ei kuitenkaan ollut vaikutusta. Tämä on kiintoisa huomio,
sillä  in  silico  -selvityksen  mukaan  SK-BR-3  -solujen  HER-3  -reseptori  sisältää
pistemutaation. Tarkempi in silico -tutkimus paljasti, että 1.62 prosenttia rintasyövistä sisältää
HER-3:n aminohappokoostumusta muuttavia pistemutaatioita. Jos käsitellään eri alatyyppejä
erikseen,  3.36  prosenttia  HER-2 -positiivisista  tapauksista  sisältää  pistemutaatioita  HER-3
-proteiinissa, kun taas vain 1.42 prosenttia HER-2 -negatiivisista tapauksista sisältää HER-3
-pistemutaatioita.  Tämä  havainto  on  mielenkiintoinen,  ja  HER-3  -pistemutaatioiden
merkitystä  HER-2  -positiivisen  rintasyövän  synnylle  ja  kehitykselle  onkin  syytä  tutkia
yksityiskohtaisesti tulevaisuudessa. Lisäksi on tärkeää selvittää, johtuuko SK-BR-3 -solujen
pertutsumabiresistenssiys  pistemutaatioista  HER-3 -reseptorissa.  Jos  näin  on,  mutaatioiden
olemassaolo  on otettava  huomioon kehitettäessä uusia,  HER-3 -reseptoriin  kohdennettavia
lääkkeitä.
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Abstract
Breast cancer is a common disease and an important cause of mortality in women. Breast
cancer  has  been  extensively  studied  during  the  last  few  decades,  which  has  led  to  the
development of potent drugs and to the identification of several breast cancer subtypes. HER-
2 positive breast cancer is one of the most well-known subtypes, and drugs which directly
target  this  receptor  and  inhibit  the  ligand  independent  signaling  pathways  have  been
developed. Some HER-2 positive breast cancers, however, are insensitive to these drugs, and
this has led to the need to develop alternative treatment methods and to find new drug targets.
HER-2/HER-3  heterodimers  are  among  the  most  promising  new  targets.  These  dimers
activate  downstream  signaling  pathways  such  as  PI3K/Akt,  which  inhibit  apoptosis  and
promote cell proliferation.
The aims of this  thesis  were to quantitate the amount of HER-2/HER-3 dimers in twelve
breast  cancer  cell  lines  and in  one gastric  cancer  cell  line using proximity ligation assay
technique,  to  examine  do  point  mutations  in  the  HER-3  receptor  affect  HER-2/HER-3
dimerization and drug response in vitro, and to determine the prevalence of these mutations in
breast cancer using in silico methods.
As expected, HER-2/HER-3 dimers were abundant in most HER-2 positive cell lines, while
HER-2 negative cell lines had only a few dimers. Additionally, the addition of pertuzumab, a
HER-2/HER-3 dimerization inhibitor,  decreased the amount  of  dimers  in  most  tested cell
lines. In vitro drug sensitivity assay confirmed that pertuzumab alone is capable of preventing
the growth of most HER-2 positive cell  lines.  However,  despite the abundance of HER-
2/HER-3 dimers,  SK-BR-3,  BT-474,  and  ZR-75-30 cells  were  insensitive  to  pertuzumab.
Curiously, in silico evaluation revealed that one of these three cell lines, SK-BR-3, contains a
point  mutation  in  the  HER-3  receptor,  which  might  explain  the  observed  resistance  to
pertuzumab.  Further  in  silico  study  revealed  that  1.62%  of  all  breast  cancers  contain
nonsynonymous point mutations in the ERBB3 gene which encodes the HER-3 protein. When
considering  different  cancer  subtypes,  3.36% of  the  119 HER-2 positive  samples  studied
contained point mutations in ERBB3, while only 1.42% of the 843 HER-2 negative samples
contained point mutation in the gene. The fact that HER-2 positive breast cancers contain
twice as many point mutations as other breast cancer subtypes is interesting, and therefore the
significance of these mutations to the onset and development of HER-2 positive brest cancer
should be carefully evaluated in the future. Additionally, it is important to investigate if the
pertuzumab resistance of SK-BR-3 cells is caused by the HER-3 point mutation. If this is the
case, the presence of HER-3 point mutations should be taken into account when new HER-3
targeted drugs are developed.
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1. Introduction
For a long time, cancer has been a major health problem worldwide, and yet the incidence of
this group of related diseases is increasing: in 2012 there were approximately 14 million new
cancer cases, and this number is estimated to grow to 24 million in the following 20 years
(Ferlay et al. 2013). Even though there are over 200 different types of cancer, only six cancer
types  (lung,  breast,  colorectum,  prostate,  stomach,  and  liver;  non-melanoma  skin  cancer
excluded) constitute 55% of all new cancer cases (Ferlay et al. 2013).
1.68 million new breast cancers in the world were diagnosed in 2012, making it the second
most  common cancer  in  both sexes with 11.9% of  all  new cases  (Ferlay et  al.  2013).  In
women, breast cancer is clearly the most common cancer with 25.2% of all new cases (Ferlay
et  al.  2013).  Since  breast  cancer  is  such  an  important  disease,  it  has  been  extensively
researched for decades: a simple PubMed search with terms “breast cancer” yields over 282
000 results. First of these publications have been published in the 19th century.
Due to the extensive research, new treatment methods  and drugs have been developed, and
diverse molecular mechanisms affecting the onset and development of breast  cancer  have
been discovered in the past decades. Several prognostic and predictive markers have been
established,  the  most  important  and  widely  researched  molecular  factors  being  HER-2,
estrogen receptor, and progesterone receptor (Cianfrocca and Gradishar 2009, Köninki 2010,
Bertos  and  Park  2011,  Gannon  et  al.  2013,  Rivenbark  et  al.  2013).  Breast  cancer  is
categorized to four different main subtypes depending on which of these receptors, if any, are
overexpressed (Norum et al. 2004, Köninki 2010, Bertos and Park 2011). This categorization
is  important  as  HER-2 positive  tumors,  for  example,  require  different  treatment  methods
when compared to tumors of other categories, such as the triple negative subtype (Norum et
al. 2004). It is therefore vital to identify the molecular variety in all new breast cancer cases in
order  to choose the right  therapy with high therapeutic  efficacy and minimal  side effects
(Norum et al. 2004, Köninki 2010, Rivenbark et al. 2013).  
It is noteworthy that even though HER-2, estrogen receptor, and progesterone recetor are the
most well-known  molecular factors associated with breast cancer, they are not the only ones.
One of the less researched molecular factors is HER-3, a close relative to HER-2 (Hamburger
2008). HER-3 forms dimers especially with HER-2 and activates PI3K/Akt pathway, which
inhibits  apoptosis  and promotes  cell  proliferation (Chang et  al.  2003, Hsieh and Moasser
2007).
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The aim of this  thesis  is  to determine the abundance of HER-2/HER-3 dimers in HER-2
positive breast cancer cell lines and to determine how the amount of these dimers correlates
with the drug response to pertuzumab, a HER-2/HER-3 dimerization inhibitor. Additionally, it
has been suggested that point mutations in the HER-3 receptor could be rather common, and
the abundance of these mutations in breast cancer is evaluated in silico (Jaiswal et al. 2013).
The possible effect of these mutations to HER-2/HER-3 dimerization is also studied.
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2. Review of the literature
2.1. Origin of breast cancer
As mentioned before, breast cancer is the most common cancer in women. There are several
different  subtypes  of  human  breast  cancer,  all  of  which  have  distinct  clinical  course,
therapeutic response, and morphology (Norum et al. 2004, Köninki 2010, Bertos and Park
2011). Due to this heterogeneity, a single mechanism of breast cancer development has been
hard to decipher. Previously it was thought that breast cancer development is a multi-step
process following a single pathway: the disease develops over an extended period of time,
beginning with dysplasia, progressing to invasive carcinoma and finally to metastatic disease
(Falkenberry and Legare 2002, Ye et al. 2004). New evidence, however, suggest that this kind
of systematic multi-step model is at least partially too simplistic, and that the development of
breast cancer involves a complex series of random mutations which, sooner or later, lead to an
invasive disease and possible cancer stem cell formation (Köninki 2010). According to recent
studies, these random mutations do not necessarily lead to a progress from well differentiated
through moderately differentiated to undifferentiated  tumors (Köninki 2010).
Mutations  in  tumor  suppressor  genes  such as  BRCA1 are  thought  to  be  important  in  the
development  of  breast  cancer  (Lee  and  Muller  2010).  Tumor  suppressor  genes  encode
proteins that are involved in cell cycle regulation, apoptosis, angiogenesis, DNA repair, and
generally in many important cellular processes inhibiting tumor formation (Köninki 2010, Lee
and  Muller  2010).  Point  mutations,  chromosomal  deletions  or  epigenetic  changes  can
inactivate  tumor  suppressor  genes  and  lead  to  tumor  formation  (Köninki  2010).  Tumor
suppressor  gene  mutations  are  often  accompanied  with  mutations  in  proto-oncogenes
(Osborne et al. 2004). These genes and their protein products are usually involved in cellular
proliferation and apoptosis,  enhancing the former and inhibiting the latter  (Osborne et  al.
2004). Protein products of proto-oncogenes are needed in normal cells, but if these genes are
mutated to oncognes, normal cellular processes and downstream signaling pathways may be
disturbed and a cell may start to grow and proliferate uncontrollably (Todd and Wong 1999).
Genes coding the members of the human epidermal growth factor receptor (HER) family are
among the best known and most important oncogenes associated with breast cancer (Osborne
et al. 2004).
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2.2. Human epidermal growth factor receptors
The  human  epidermal  growth  factor  receptor  family  consists  of  four  membrane-bound
receptor proteins: HER-1 (EGFR), HER-2, HER-3, and HER-4 (Olayioye et al. 2000, Hsieh
and  Moasser  2007).  These  receptors  are  expressed  in  various  tissues  of  mesenchymal,
epithelial  and  neuronal  origin  (Köninki  2010).  Each  receptor  of  the  HER family  has  an
extracellular, transmembrane, and intracellular domain (Burges et al. 2003). The extracellular
domains of HER-1, HER-3, and HER-4 bind ligands such as epidermal growth factor (EGF)
molecules  (Burges  et  al.  2003).  The  extracellular  domain  also  contains  a  dimerization
subdomain (more detailed information in section 2.6.). The transmembrane domain attaches a
receptor  to  cell  membrane (Burges  et  al.  2003).  The  intracellular  protein  tyrosine  kinase
domain  activates  downstream signaling pathways  (Olayioye  et  al.  2000).  These pathways
affect growth, survival, and proliferation of a cell.
In normal cells the activation of HER family receptors and consequential cellular signaling
are strictly regulated. If this regulation does not work as it should, signaling pathways may
become overactive and a cell may become malignant (Olayioye et al. 2000). This leads to
various alterations of transport pathways and overall changes in biological behaviour of the
cell.  It has, for example,  been reported that even though the receptor tyrosine kinases are
primarily membrane proteins, the members of HER family can be abundant in the nucleus of
cancer cells (Wang et al. 2010).
2.3. HER-2 in breast cancer  
Human epidermal growth factor receptor 2 (HER-2) is a widely researched receptor of the
HER family as well as an important target of therapy in breast cancer. HER-2 is encoded by
the ERBB2 gene which is located in chromosome 17q (Schecter et al. 1984, King et al. 1985).
It has been estimated that the ERBB2 gene is amplified in 10–25% of breast cancers (Seshadri
et al. 1993, Andrulis et al. 1998, Owens et al. 2004, Köninki 2010, Harbeck et al. 2013). The
estimated proportion of breast cancer with ERBB2 amplification has steadily declined during
the last  few decades,  and the percentage is  probably closer to the lower end of the scale
(Köninki 2010). A  normal cell has only two copies of the  ERBB2 gene, whereas a HER-2
positive  cell  may  contain  up  to  100  copies  of  the  gene  (Perez  and  Baweja  2008).
Amplification of the ERBB2 gene leads to HER-2 protein overexpression and consequently to
excessive  activation  of  the  downstream signaling  pathways  (Slamon  et  al.  1987).  HER-2
overexpression is  associated with  a  more aggressive  clinical  course and poorer  prognosis
when  compared  to  breast  cancer  subtypes  not  overexpressing  HER-2  (Perez  and  Baweja
2008).
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2.4. The ERBB3 gene and the HER-3 receptor
2.4.1. The ERBB3 gene
Human epidermal growth factor receptor 3 (HER-3) is coded by the  ERBB3 gene, which is
located on chromosome 12q13.2 (Sithanandam and Anderson 2008, Koutras et al. 2010). The
gene is 23.2 kb in size and it consists of 28 exons (Sithanandam and Anderson 2008). The
extracellular domain coding sequence has 43–45% homology and the intracellular domain
coding sequence has 60–63% homology with the  ERBB2 gene (Sithanandam and Anderson
2008). A full-length  ERBB3  gene transcript consists of 4080 nucleotides and 1342 codons
(Sithanandam and Anderson 2008). Additionally, there are five truncated  ERBB3 transcripts
which range from 1.4 kb to 2.3 kb in size (Sithanandam and Anderson 2008). The truncated
transcripts code for both secreted proteins and membrane-bound proteins (Sithanandam and
Anderson 2008). It has been shown that secreted transcripts of the ERBB3 gene, especially a
protein called p85-sHER-3, bind neuregulins (NRGs, HER-3 ligands) and reduce the ligand
activity of NRGs in breast cancer cells (Sithanandam and Anderson 2008).
The promoter region of the ERBB3 gene is GC rich (65%) and it does not contain a TATA box
(Sithanandam and Anderson 2008). Instead, five potential nuclear factor binding sites have
been identified in the promoter region. It is not precisely known which transcription factors
are involved in the activation of the ERBB3 gene, but it is believed that the Sp1 transcription
factor is involved in the process as it binds to upstream of intron 1 enhancers (Sithanandam
and Anderson 2008). Additionally, overexpression of AP transcription factors as well as the
presence of α6β4 integrin have been shown to increase the  ERBB3  mRNA levels in breast
cancer  cells  (Sithanandam  and  Anderson  2008).  Estrogen,  on  the  other  hand,  decreases
ERBB3 mRNA levels in estrogen receptor-positive breast cancer cell lines (Bates and Hurst
1997, Revillion et al. 2003, Sithanandam and Anderson 2008).
2.4.2. Overview of the HER-3 receptor
Human epidermal growth factor receptor 3 (HER-3) is a widely expressed protein in human
tissues. It is detected in brain, liver, kidney, spinal cord, prostate, lung, and mammary gland
(Sithanandam and Anderson 2008). HER-3 could be considered the little brother of HER-2:
even though HER-3 is not as widely researched as HER-2, it is increasingly investigated for
its  role  in  the  onset  and  development  of  cancer.  HER-3  receptor  is  activated  by  ligand
(neuregulin-1 (NRG-1) and neuregulin-2 (NRG-2)) binding (Stern 2008). The intracellular
kinase  domain  of  HER-3  is  inactive,  and  it  is  therefore  unable  to  initiate  downstream
signaling pathways on its  own (Hsieh and Moasser 2007,  Koutras et  al.  2010).  However,
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HER-3  can  dimerize  with  other  receptors,  most  importantly  with  HER-2,  to  increase
downstream signaling  (Koutras  et  al.  2010).  HER-3 receptors  have  been  estimated  to  be
overexpressed in 20–30% of invasive breast carcinomas (Koutras et al. 2010).
Such as all members of the HER family, a single HER-3 receptor has an extracellular domain,
a  transmembrane  domain,  and  an  intracellular  domain.  HER-3  receptor  consists  of  1342
amino acid residues. The atomic mass of HER-3 is 180 kDa, of which up to 30 % consists of
glycosyl groups (Sithanandam and Anderson 2008).
2.4.3. Extracellular domain of HER-3
The extracellular domain of HER-3 consists  of 624 amino acid residues which form four
subdomains:  I,  II,  III,  and  IV (Cho and  Leahy 2002,  Sithanandam and  Anderson 2008).
Domain I consists of 190 residues and it has a β-helical, small disulfide-containing modules
containing structure. Domain II also consists of ~190 amino acid residues but it exists in a
more extended conformation when compared to domain I. Domain III contains 120 residues
and its  structure is  similar to domain I.  Domain IV consists  of 120 residues and it  is  an
extended repeat of seven small disulfide-containing modules, similar to those in domain II
(Cho and Leahy 2002).  The PDB structure of the extracellular domain is shown in figure 1.
When a ligand is not bound to HER-3, domains II and IV interact with each other and the
residues 242–259 of domain II  form a β-hairpin loop which keeps the receptor  in  closed
conformation  preventing  the  dimerization  arm  of  domain  II  from  interacting  with  other
receptors (Sithanandam and Anderson 2008). Domains I and III are responsible for ligand
bindind and, unlike in HER-1, domain III ligand binding is dominant in HER-3 (Sithanandam
and Anderson 2008).  When the receptor  binds  a  ligand,   domains  I  and III  form a rigid
structure and the domain II expands and interacts with the dimerization domain of another
ligand-bound member of the HER family to form dimers (Sithanandam and Anderson 2008).
Domain IV interacts with domain II, enhancing the ligand binding affinity of the receptor 20-
to  40-fold  (Cho  and  Leahy  2002).  Domain  IV,  however,  is  not  directly  involved  in  the
dimerization process (Cho and Leahy 2002).
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Figure 1. The PDB structure (1M6B) of the extracellular domain of HER-3. Domains I (red) and III (blue) have
similar structure, and so do domains II (green) and IV (yellow).
2.4.4. Transmembrane region of HER-3
The transmembrane domain of HER-3 is a single helical structure that contains 21 amino acid
residues. It  has one GXXXG consensus sequence that enhances the efficiency of receptor
homodimerization (Sithanandam and Anderson 2008).  Other  members of the HER family
contain two GXXXG concensus sequences, and due to this it is believed that HER-3 is less
able to form homodimers when compared to for example HER-2 (Sithanandam and Anderson
2008).  The  relative  inability  of  HER-3  to  form  homodimers  is  considered  to  promote
heterodimerization  especially  with  HER-2  (Sithanandam  and  Anderson  2008).  The  PDB
structure of the transmembrane region of a homodimer formed by two HER-3 receptors is
shown in figure 2.
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Figure 2.  The PDB structure (2L9U) of the transmembrane region of  a homodimer formed by two HER-3
receptors.
2.4.5. Intracellular region of HER-3
The intracellular domain of HER-3 consists of 697 amino acid residues, of which 268 form
the cytoplasmic kinase domain. The amount of amino acids in different HER receptors vary
from 1210 (HER-1) to 1342 (HER-3), but the amount of amino acids (268) in the kinase
domain is conserved in all the members of HER family.  192 of the total  268 amino acid
residues are identical in HER-1, HER-2 and HER-4. Of these 192 identical residues, 144 are
conserved in HER-3 (figure 3).
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Figure 3. The sequences of kinase domains of HER-1, HER-2, HER-3, and HER-4 aligned. Amino acids that are
identical in all receptors (except in HER-3 in some cases) are highlighted in gray. Red highlightion shows the
HER-3 residues which are different from the conserved residues of other receptors. Sequences were obtained
from GenBank (http://www.ncbi.nlm.nih.gov/genbank/).
Because the amino acid composition of the kinase domain of HER-3 differs significantly from
other members of the HER family, and because the intracellular domain of HER-3 does not
become autophosphorylated, the receptor is generally considered to have a very low kinase
activity  (100-fold  reduced  when  compared  to  other  members  of  the  HER  family)
(Sithanandam and Anderson 2008, Shi et al. 2010). Some of the amino acid changes are more
significant  than  others,  and  especially  the  change  of  glutamate  740  of  other  kinases  to
histidine in HER-3, the change of aspartate 815 of other kinases to asparagine in HER-3, and
the  change  of  asparagine  of  other  kinases  to  phenylalanine  in  HER-3  are  thought  to  be
important inactivating factors. E740 is indirectly involved in ATP binding, D815 functions as
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a catalytic base in protein kinases deprotonating substrate hydroxyl group, and mutated F734
in HER-3 provides hydrophopic interactions that stabilize the inactive conformation of kinase
domain (Jura et al. 2009, Shi et al. 2010).
Even though the dysfunctional kinase activity of HER-3 has been established, it is not fully
understood how HER-3, then, is able to enhance the phosphorylation of HER-2 in a HER-
2/HER-3 dimer (Sithanandam and Anderson 2008).  One explanation to this  could be that
HER-3 recruits  another  cytoplasmic  kinase  that  is  responsible  for  the  phosphorylation  of
HER-2 (Sithanandam and Anderson 2008). This scenario, though, is unlikely, and it is more
probable  that  allosteric  interactions  between  kinase  regions  of  HER-2  and  HER-3  are
responsible for the phosporylation and subsequent activation of HER-2 (Sithanandam and
Anderson 2008). It has been suggested that even though HER-3 is catalytically inactive, it can
serve as an activator of other members of the HER family (Slamon et al. 1987,  Jura et al.
2009).  This  involves  the formation of asymmetric  dimers  between the kinase domains  of
HER-3 and the kinase domain of another member of the HER family (Zhang et al. 2006, Jura
et al. 2009). One of the kinase domain functions as an activator and the other functions as a
receiver. The activator kinase plays a role similar to that of cyclin in cyclin-dependent kinases,
stimulating autophosphorylation and activation of the receptor kinase (Jura et al. 2009). Thus,
even though HER-3 cannot  function  as  the  receiver  or  become autophoshorylated,  it  can
function as the activator kinase and activate other members of the HER family (Jura et al.
2009).
A schematic diagram of the intracellular kinase domain of a HER family receptor is shown in
figure 4. Figure 5 shows the PDB-structure of intracellular domain of HER-3.
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Figure 4. A schematic diagram of the intracellular kinase domain of a HER family receptor. The juxtamembrane
segment attaches the kinase domain to the transmembrane domain of the receptor. Juxtamembrane domain also
interacts with the C-lobe and participates in dimer formation when a ligand is bound to the extracellular domain
of  the  receptor.  C-lobe,  N-lobe,  helix  αC,  and  activation  loop  form  the  actual  kinase  domain,  which
phosphorylates the C-terminal tail. Helix αC is an important element in kinase regulation. When the receptor is
in inactive conformation, activation loop is tightly packed inside the active site of helix αC. When the receptor is
activated, conformations of both helix αC and activation loop change and the kinase domain becomes able to
phosphorylate its  target.  C-terminal  tail  contains  three  phosporylation sites  which mediate the  activation of
downstream signaling pathways. Adapted from Jura et al., (2009).
Figure 5. PDB-structure (3KEX) of the intracellular domain of HER-3. Helix αC, activation loop, N-lobe, and
C-lobe form the actual kinase domain. In HER-3, αC/β3 loop contains mutated F734, which stabilize the inactive
conformation of activation loop and helix αC. AMP-PNP is a nonhydrolyzable analogue of ATP which, in active
kinases, is used to phosphorylate the C-terminal tail. P-loop is important to the correct localization of ATP.  C-
lobe of the activator kinase (e.g. HER-3) can interact with the N-lobe of the receiver kinase (e.g. HER-2) and
help it to become autophosphorylated.
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2.4.6. HER-3 receptor in breast cancer
Even though HER-3 alone or as a homodimer is inactive, it can active several downstream
signaling  pathways  (PI3K/Akt,  PLCγ/PKC,  Jak/Stat,  and  MEK/MAPK)  through
heterodimerization with other members of the HER family, especially with HER-2 (Metzger-
Filho et al. 2013, Ma et al. 2014). This heterodimerization, discussed in more detail in section
2.6.2., is important to breast cancer development: it has for example been observed that the
existence of HER-3 receptors is required to maintain the tyrosine kinase activity of  HER-2
(Ma et al. 2014).
It is common that the expression level of the ERBB3 gene is increased in breast cancer (Ma et
al. 2014). It has been evaluated by real-time PCR that ERBB3 mRNA levels in different breast
cancers show 100-fold variation, and that the expression level is on average 46% higher in
cancer cells than in normal cells (Sithanandam and Anderson 2008). HER-3 protein, on the
other hand, is detectable in 50–70% of human breast cancers, and the levels of the protein are
higher  in  cancer  cells  than  in  normal  cells  in  18–29  % of  the  cases  (Sithanandam and
Anderson 2008). Overexpression of HER-3 has been associated with larger tumor size and
with  increased  metastasis  and  recurrence  (Ma  et  al.  2014).  However,  reports  have  been
controversial: while most of the studies support the above mentioned obsevations which lead
to  poorer  prognosis,  some  have  reported  that  HER-3  overexpression  actually  improves
prognosis (Ma et  al.  2014).  A few theories have been proposed to  explain these contrary
observations.  One  of  these  theories  tries  to  explain  why,  unlike  expected,  HER-3
overexpression can improve the prognosis of breast cancer: the ERBB3 gene can be expressed
in an alternatively spliced forms generating a truncated, soluble isoform of the HER-3 protein
(p85-sHER-3)  (Ma et  al.  2014).  This  isoform can bind to  NRG-1 and NRG-2 with  high
affinity, thereby blocking the binding of these ligands to the HER-3 receptors located on the
cell surface. Increased expression of the ERBB3 gene leads to elevated amounts of p85-sHER-
3 and consequently to increased blockage of ligand binding. When ligand binding is blocked,
downstream  signaling  cannot  occur  (Ma  et  al.  2014).  According  to  second  theory,  the
localization (on the cell membrane, in the cytoplasm, or in the nucleus) of HER-3 receptors
can affect their activity (Ma et al. 2014). Thus, higher concentration of the molecules does not
necessarily  correlate  with  the  activity  of  downstream signaling  pathways.  If  most  of  the
receptors are located in the cytoplasm or in the nucleus, they can't bind their ligands or form
dimers  with  other  receptor  tyrosine  kinases,  and  consequently  downstream  signalling
pathways cannot be activated. Several factors, such as the concentration of NRGs, can affect
the cellular location of HER-3 receptors and therefore have an impact on the HER-2/HER-3
heterodimer mediated signaling (Ma et al. 2014).
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2.5. Point mutations in the ERBB3 gene and in the HER-3 protein
2.5.1. Point mutations in the ERBB3 gene
528 single nucleotide polymorphisms (SNP) in the ERBB3 gene have been found (Raghav and
Sharma 2013). 352 of these mutations are located in introns, while the rest 176 are located in
exons.  Of  the  exon  mutations  79  are  nonsynonymous  missense  SNPs,  while  37  are
synonymous  mutations  (Raghav  and  Sharma  2013).  Rest  of  the  exon  SNPs  consist  of
frameshift mutations, mutations in the untranslated regions, and mutations in near-gene 5' and
near-gene 3' (Raghav and Sharma 2013). Of the 79 nonsynonymous missense mutations 29
are  identified  as  native  protein  conformation  changing (Raghav and Sharma 2013).  Such
protein conformation altering mutations in the ERBB3 gene are most common in gastric and
colon cancers (12% and 11% of all cancer cases of the named type, respectively.) (Jaiswal et
al.  2013).  2–4%  of  breast  cancers,  on  the  other  hand,  have  been  reported  to  contain
nonsynonymous point mutations in the ERBB3 gene. The significance of these mutations to
the onset and development of cancer has not been evaluated (Jaiswal et al. 2013).
2.5.2. Point mutations in the HER-3 receptor
A few  recurrent  point  mutations  in  the  HER-3  protein  have  been  found.  Most  of  these
mutations are located in the extracellular region of HER-3, but some are also located in the
intracellular domain (Jaiswal et al. 2013). Nine of the mutation positions (V104, A232, P262,
G284, D297, G325, T355, S846 and E928; seven in the extracellular region and two in the
kinase  domain)  have  been  shown  to  exist  in  multiple  samples,  and  therefore  they  are
identified as mutational hot spots (Jaiswal et al. 2013). Two of the nine hot spot mutations
(valine 104 to methionine and glutamate 928 to glutamine) are present in breast cancer while
the other seven are primarily found in colon and gastric cancers (Jaiswal et al. 2013). In each
hot spot position, the original amino acid is substituted to a same new amino acid in most
cases. This indicates that the changes could be functionally relevant and that there could be
some driving force for the mutations (Jaiswal et al. 2013).
One of the seven mutational hot spots found in the extracellular domain of HER-3 (valine 104
to  methionine)  is  in  the  subdomain  I,  five  (alanine  232  to  valine,  phenylalanine  262  to
histidine/serine, glycine 284 to arginine, aspartate 297 to tyrosine, and glycine 325 to argine)
are in the subdomain II, and one (threonine 355 to alanine/isoleucine) is in the subdomain III
(Jaiswal et al. 2013). The mutations at V104, A232 and G284 are located in the interface of
subdomains I and II,  and it has been suggested that they might affect the structure of the
disulfide-containing modules in domain II (Jaiswal et al. 2013). This might lead to enhanced,
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or possibly decreased, dimerization activity. P262 is thought to participate in the interactions
between domains II and IV which keep the receptor in closed conformation. Therefore it is
possible that HER-3 receptors having a mutated amino acid residue at position 262 are more
easily converted to open conformation than are wild type receptors (Jaiswal et al. 2013). D297
is  located  near  the  dimerization  arm  of  subdomain  II  and  it  has  an  important  role  in
heterodimerization (Jaiswal et al. 2013). Mutations of this residue might hence increase the
number of HER-2/HER-3 dimers. G325 and T355 are located in the border region between
subdomain  II  and  III  of  the  extracellular  domain  (Jaiswal  et  al.  2013).  Rather  large
conformational changes occur in the border region, and mutations of residues 325 and 355
might have an impact on these transitions.
The two mutational hot spots found in the intracellular segment of HER-3 (serine 846 to
isoleucine and glutamate  928 to glycine)  are  both located in  the kinase domain.  S846 is
located near the path taken by the to be phosphorylated C-terminal tail  in dimeric kinase
structures (Jaiswal et al. 2013). E928 is also believed to be involved in heterodimer formation.
Significance of the mutations in this residue, however, is not known (Jaiswal et al. 2013).
Several of the above mentioned hot spot mutations of HER-3 receptor promote oncogenic
signaling  in  cancer  cells  if  active HER-2 receptors  are  present  (Jaiswal  et  al.  2013).  For
example, HER-3 receptors containing mutations at V104, A232, and P262 can form dimers
with HER-2 and activate downstream signaling pathways without the HER-3 ligands NRG-1
and NRG-2 (Jaiswal et al. 2013). However, the activity of HER-3 receptors containing these
mutations do increase when NRG-1 or NRG-2 is added, and therefore it is believed that these
mutations do not necessarily force the receptor to open conformation but only rather make the
closed conformation less favourable than in wild-type receptors (Jaiswal et al. 2013).
In addition to the hot spot mutations, several other important point mutations in the HER-3
receptor  have  been reported,  most  of  them being located  in  domains  I,  II  and III  of  the
extracellular segment. Glycosylation site Asn414, for example, has been found to be critical to
regulation of HER-3 function: if the asparagine residue is mutated into glutamine, the receptor
can dimerize with HER-2 in the absence of ligand and thus the cancerous properties of a cell
are enhanced (Sithanandam and Anderson 2008). Other non hot spot mutations which have
been reported to disrupt the conformation of HER-3 receptor include V89M, V105G, C290Y,
T389K, I418N, R669C, I744T, and A1131T (Jaiswal et al. 2013, Raghav and Sharma 2013).
All these mutations are considered as potentially disease causing (Raghav and Sharma 2013).
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2.6. Dimerization of HER family receptors
2.6.1. Overview of the dimerization of HER family receptors
All members of the HER family form hetero- and homodimers with each other in order to
convert  extracellular  signals into intracellular  signals.  Before receptors can dimerize,  they
must bind an associated ligand that changes the conformation from closed to open (Harbeck et
al. 2013). HER-2 is an exception as it continuously exists in the open conformation and does
not  bind  any known ligand (Harbeck et  al.  2013).  When  two receptors  that  are  in  open
conformation have dimerized, they can be autophosphorylated (Burgess et al. 2003, Zhang et
al.  2006).  Phosphorylation is  followed by receptor  internalization and further downstream
signaling (Wang et al. 2010, Harbeck et al. 2013).
2.6.2. HER-2/HER-3 dimer
Of all the dimers formed by the members of the HER family, HER-2/HER-3 heterodimers are
the most potent activators of downstream signaling (Amin et al. 2010). It has been suggested
that cell transformation and breast carcinoma progression might be triggered by HER-2/HER-
3 heterodimers: HER-3 is considered as an irreplaceable dimerization partner of HER-2, and
it is thought to be required for proliferation of HER-2 positive breast cancer cells (Holbro et
al. 2003, Choi et al. 2012, Green et al. 2014). It is noteworthy, though, that cancer cells with
no or few HER-3 molecules are able to maintain similar levels of phosphorylated HER-2
receptors as are cells with high levels of HER-3 (Holbro et  al.  2003). However,  the cells
containing only a few HER-3 receptors are proliferatively blocked, which confirms the great
importance of HER-3 in breast cancer (especially in HER-2 positive subtype) development
(Holbro et al. 2003). The antiproliferative properties resulting from the loss of HER-3 could
not be replaced by HER-1 or HER-4 proteins (Holbro et al. 2003).
As reviewed in Holbro et al. (2003), the importance of cooperative actions of HER-2 and
HER-3 in the development of breast cancer has been further demonstrated in several studies
which have shown that blocking of HER-2 also decreases signaling ability of HER-3 (Lane et
al. 2000, Neve et al. 2000, Basso et al. 2002, Motoyama et al. 2002). In addition to the in vitro
models, an  in vivo  study of transgenic mammary tumors showed elevated levels of tyrosine
phosphorylated HER-3 in HER-2 positive tumors, while the levels of phosphorylated HER-1
or HER-4 were not increased (Holbro et al. 2003).
All  the  above  mentioned  observations  suggest  that  HER-3  is  the  most  important  and
biologically  relevant  partner  of   HER-2  in  HER-2  positive  breast  cancers:  HER-3  as  a
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dimerization partner to HER-2 is believed to be required to fulfill the full signaling potential
of HER-2 positive breast cancer cells (Holbro et al. 2003). In addition to their potency, HER-
2/HER-3  dimers  are  common  in  breast  cancer,  especially  in  HER-2  positive  subtype.
According to one study, HER-2/HER-3 dimers are detectable in 13.1% of all breast cancers
and  in 73% of HER-2 positive tumors (Green et al. 2014).
Dimerization of HER-2 and HER-3 promotes cell proliferation and inhibits apoptosis mainly
by  enhancing  phosphatidylinositide  3-kinase  (PI3K)/Akt  signaling  pathway  (Kruser  and
Wheeler 2010, Choi et al. 2012). The PI3K/Akt pathway is a classic survival pathway that is
activated in many different cancers (LoPiccolo et al. 2008). The pathway is iniatiated when
cell  membrane located  PI3K is  activated.  Members  of  the  HER family,  integrings  or  G-
protein-coupled receptors, for example, can activate PI3K (LoPiccolo et al. 2008). Activated
PI3K catalyzes phosphorylation of phosphoinositides generating phosphatidylinositol-3,4,5-
triphosphate (PI(3,4,5)P3) and phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2) (LoPiccolo
et al.  2008).  Phosphorylated phosphoinositides bind to Akt,  a serine/threonine kinase,  and
cause it  to  move to cell  membrane where it  is  activated.  Akt  is  known to exist  as  three
isoforms, Akt1, Akt2 and Akt3. Akt isoforms are structurally homologous (LoPiccolo et al.
2008),  and  they  are  activated  similarly  (not  explained  here  in  detail).  All  Akt  isoforms
phosphorylate a consensus sequence RXRXX(S/T) present in numerous proteins. Because the
consensus sequence is rather common, several Akt substrates such as FoxO, BAD, IKK, and
most  importantly  mTOR  have  been  identified  (LoPiccolo  et  al.  2008).  These  substrates
control  important  cellular  mechanisms  like  cell  cycle  progression,  transcription,  and
translation (LoPiccolo et al. 2008).  
HER-2/HER-3 heterodimers  enhance PI3K/Akt pathway through direct  HER-3 binding to
PI3K. HER-3 contains six tyrosine-binding sections, and thus it has the highest affinity for
PI3K among all  of the receptors of HER family;  no other member of the HER family is
capable of activating the PI3K/Akt pathway as strongly as HER-3 (Holbro et al. 2003, Stern
2008, Green et al. 2014).
Regardless  of  the  significance  of  HER-3  in  the  activation  of  PI3K/Akt  pathway,  it  is
noteworthy that HER-3 alone or as a homodimer is not able to activate the pathway (Green et
al. 2014). Additionally, despite the indisputable importance of the PI3K/Akt pathway in breast
cancer  development,  HER-2/HER-3  dimers  can  also  activate  other  downstream signaling
pathways such as PLCγ/PKC, Jak/Stat, and MEK/MAPK (not described here in detail) (Ma et
al. 2014).
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2.6.3. HER-2/HER-3 dimer targered therapy
Due to the fact that HER-2/HER-3 dimers are a rather new target for drug development, only
one agent, pertuzumab, directly inhibiting the dimer formation is currently in clinical testing.
Pertuzumab  is  a  humanized  monoclonal  IgG1  antibody  that  binds  to  the  extracellular
dimerization domain (subdomain II) of HER-2 receptor, efficiently blocking ligand-dependent
heterodimerization with other members of the HER family, especially with HER-3 (Baselga J
2010, Harbeck N et al. 2013, Malenfant et al. 2014). This blocking leads to the inhibition of
downstream signaling pathways and consequently to  increased rates of apoptosis  and cell
growth suspension (Malenfant et al. 2014).
2.6.4. Combination of pertuzumab and trastuzumab in the treatment of breast cancer
Pertuzumab binds to the extracellular domain of HER-2 in a similar fashion as trastuzumab,
another  humanized  monoclonal  antibody  used  to  treat  HER-2  positive  breast  cancer.
Trastuzumab, like pertuzumab, activates antibody-dependent cellular cytotoxicity (Zagouri et
al.  2013).  Pertuzumab  and  trastuzumab,  however,  bind  to  different  epitopes  of  HER-2:
pertuzumab binds to the center of the subdomain II of HER-2 extracellular domain, while
trastuzumab binds to the subdomain IV of the extracellular domain (Harbeck N et al. 2013).
Trastuzumab  inhibits  ligand-independent  HER-2  signaling,  pertuzumab  prevents  HER-
2/HER-3 dimerization,  and together they induce apoptosis  both  in vitro  and  in vivo (Lee-
Hoeflich et al. 2008, Scheuer et al. 2009, Harbeck N et al. 2013). Results from several studies
have  suggested  that  this  kind  of  treatment  of  HER-2  positive  breast  cancer  with  two
monoclonal antibodies which have different mechanisms of action and distinct binding sites
results in a more complete blockage of downstream signaling pathways when compared to a
treatment with either of the antibodies alone (Ma et al. 2014). It is noteworthy, though, that  in
HER-2 negative breast cancers a combination treatment with trastuzumab and pertuzumab is
not  more  effective  than  a  treatment  with  pertuzumab  alone  (Zagouri  et  al.  2013).
Complementary mechanisms of action of trastuzumab and pertuzumab are shown in figure 6.
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Figure 6. Compelentary mechanisms of action of trastuzumab and pertuzumab. Image adapted from Harbeck et
al., (2013) and Malenfant et al., (2014).
2.7. Theoretical backgroung of the methods used in this study
2.7.1. Proximity ligation assay
In proximity ligation assay (PLA) two interacting, closely located (maximum distance 30 nm)
proteins  can  be  detected  and  quantitated  (Söderberg  et  al.  2006).  PLA is  based  on  the
simultaneous  and  proximate  recognition  of  target  proteins  by  an  affinity  probe  pair.
(Fredriksson et al. 2002). At the beginning of the assay, two primary antibodies are incubated
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with samples  such as  fixed cells.  After  the primary antibodies  have bound to their  target
proteins, secondary antibodies conjugated with oligonucleotides (around 40 nucleotides long
each) are added. Two secondary antibodies, each recognizing only one primary antibody, are
used. Linear connector oligonucleotides are added after the secondary antibodies and, if the
target proteins are sufficiently close to each other, a circular structure is formed and ligated by
DNA ligase (Söderberg et al. 2006). Nucleotides, fluorescently labeled oligonucleotides and
DNA polymerase (phi29) are then added. The oligonucleotide chain of one of the secondary
antibodies   functions  as  a  primer  for  rolling  circle  amplification  reaction  that  uses  the
previously formed circle as a template (Fredriksson et al. 2002). The circle is duplicated up to
1000 times, and all the generated copies of the circle are covalently linked to each other. The
fluorescently  labeled  oligonucleotides  then  hybridize  with  the  nucleotides  in  the  product
molecule generating a fluorescent signal visible by fluorescent microscopy (Fredriksson et al.
2002). Theoretically, each dimer produces a single dot and therefore it is possible to count the
total amount of dimers in a single cell (Fredriksson et al. 2002).
A simple series of pictures showing the principle of the assay is shown in figure 7. It should
be noted, though, that there are also alternative protocols for PLA, but they are not presented
here as they were not used in this study (Anonym 2010).
Figure 7. A simple series of pictures showing the principle of PLA.   In (1.), primary antibodies have bound to
the target proteins. In (2.), secondary antibodies to which oligonucleotide chains have been attached have bound
to the primary antibodies. In (3.), linear connector oligonucleatides (red bands) have been added, and a circular
structure  has  been  formed  and  ligated  by DNA ligase  (white).  In  (4.),  DNA polymerase  (not  shown)  has
multiplied the circle, and fluorescently labeled oligonucleotides (red dots) have hybridized with the nucleotides
in the product molecule. Adapted from anonym (2010).
2.7.2. In vitro drug sensitivity assay
In  vitro  drug  sensitivity  assay  was  performed  using  a  commercial  kit.  According  to  the
manufacturer, “membrane-permeant calcein AM is cleaved by esterases in live cells to yield
the  cytoplasmic  green  fluorescence”  (Anonym  2014).  Membrane-impermeant  ethidium
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homodimer-1, on the other hand, labels nucleic acids of dead (membrane-compromised) cells
with red fluorescence (Anonym 2014).  
27
3. Main goals of the thesis
The main goals of this thesis were:
1. To quantitate the amount of HER-2/HER-3 dimers in different HER-2 positive cancer cell
lines using proximity ligation assay and to test how pertuzumab affects the dimerization.
2. To study the drug sensitivities of different HER-2 positive cancer cell lines to pertuzumab
and trastuzumab, and to compare the obtained results to the results of proximity ligation assay
experiments.  The previous observation that  a combination treatment  with pertuzumab and
trastuzumab leads to a more complete blockage of downstream signaling pathways than either
of these drugs alone was also further evaluated.
3. To evaluate the abundance and the possible importance of HER-3 point mutations in breast
cancer, especially in the HER-2 positive subtype, using  in silico  methods. Addtionally, the
relationship between HER-3 point mutations and pertuzumab sensitivity was tested in vitro.
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4. Materials and methods
4.1 Cell lines
The human breast cancer cell lines BT-474, HCC1419, MDA-MB-361, MDA-MB-453, MCF-
7,  SK-BR-3,  UACC-893,  and  ZR-75-30  were  obtained  from  the  American  Type  Tissue
Culture Collection,  and the cell  line EFM-192A was obtained from the German Resource
Center for Biological Material. The human oesophagus/gastric carcinoma cell line OE19 was
obtained from the European Collection of Cell Cultures. The human breast cancer cell line
JIMT-1 has been established in the laboratory of Cancer  Biology,  University of Tampere,
Finland (Tanner et al. 2004). Cells were grown under conditions recommended for each line.
4.2. Proximity ligation assay
4.2.1 Basic protocol
Proximity ligation assay (PLA) was performed using Duolink In Situ Fluorescense kit (Olink
Biosciences, Uppsala, Sweden). Before starting the PLA protocol cells were trypsinated and
deposited  on  8  well  Nunc  Lab-Tek  II  Champer  slides  (Thermo  Fisher  Scientific  Inc.,
Waltham, MA, USA). Cells were allowed to attach and grow to ~80% confluency before they
were fixed (10 minutes in 10% neutral-buffered formalin) and permeabilized (2,5 minutes in
0,25 % Triton-X 100). After fixation and permeabilization cells were blocked with Duolink
blocking  solution  for  30  minutes  in  a  pre-heated  humidity  chamber  at  37°C.  After  the
blocking step cells were washed with PBS and incubated with two primary antibodies (anti-
HER-2 (rabbit mAb, Epitomics EP1045Y, concentration unknown, diluted 1:500) and anti-
HER-3  (mouse  mAb,  Dako  DAK-H3-IC,  concentration 200  µg/ml,  diluted  1:100))  in
humidity chamber at 37°C for 60 minutes. Cells were then washed with PBS and incubated
with diluted PLA probe solution in humidity chamber at 37°C for 60 minutes. After this cells
were incubated 30 minutes with ligation solution followed by a wash step and 100 minutes
incubation with amplification solution, both incubations taking place at 37°C in a humidity
chamber.  Finally,  slides were dried and mounted with Vectashield mounting medium with
DAPI.
An Axio Apotome microscope (Carl  Zeiss Microscopy) equipped with an AxioCam Mrm
camera  using  a  63x  oil  immersion  objective  (Zeiss  Plan-Neofluar) was  used  for  PLA
microscopy. Depending on cell line, 2–4 fields of view were used and 52–86 individual cells
were imaged. 15 stack images with a slice distance of 1.000 µm were taken from each field of
view. Exposure time of 400 ms was used for the red dye and exposure time of 10 ms was used
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for DAPI.
Dimers were visualized as distinct fluorescent dots (diameter 0.5-1.5 µm). ImageJ software
was used to quantitate the dots in image focus stacks. Every second image of each image
focus stack was used, and thus the distance between each analyzed image in each stack was 2
µm. The images were converted to 8-bit images and thresholded appropriately (pixel intensity
values between 30 and 255 were used). After thresholding, analyze particles -tool of imageJ
was used to calculate total amount of dimers in image stacks. The amount of dimers in a few
images was manually counted to evaluate the automated protocol.
4.2.2 PLA for pertuzumab-sensitized cells
After the basic proximity ligation assay protocol had been optimized, PLA was performed for
pertuzumab-sensitized  cells.  The  cells  were  first  deposited  on  8-well  chamber  slides  and
allowed to attach overnight. After the cells had attached, 20 µg/ml pertuzumab was added into
the non-control wells and the cells were incubated for 72 hours. A PLA protocol identical to
the protocol described in section 4.2.1 was then performed.
4.3. In vitro drug sensitivity assay
The effects of trastuzumab, pertuzumab, and the combination of these drugs on the growth of
HER-2 overexpressing cells were examined by LIVE/DEAD Viability/Cytotoxicity Kit (Life
Technologies, Carlsbad, CA, USA). HER-2 and HER-3 negative MCF-7 and MDA-MB-231
cell lines were used as negative controls. Cells were first trypsinized and plated at suitable
densities (3000–5000 cells per well) in 96-well tissue culture plates and they were allowed to
attach overnight before drug addition. The effects of both trastuzumab and pertuzumab were
tested at a concentration of 20 µg/ml. The number of viable cells was determined at 72 h after
drug addition.
EVOS FL Auto Cell Imaging System (Life Technologies) with a 10x dry (air) objective was
used  to  image  the  cells.  Four  images  from  each  well  containing  a  sample  were  taken
manually.
In most of the cell lines, the living cells were too confluent to be counted separately. Because
of this, the total amount of cells in each image had to be calculated using an indirect method.
First, the surface area of living cells in every sample was determined using imageJ. Then the
total  amount of ZR-75-30 cells  were manually counted and the average surface area of a
single cell was determined. This average surface area was then used to derive the total amount
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of living cell in every cell line. ZR-75-30 cells were used as reference because they were the
least confluent of all cell lines and thus relatively easy to count. Dead cells were counted
manually because there were relatively few of them in each cell line. When the amount of
both dead cells and living cells had been obtained, a ratio of the amount of living cells divided
by the number of dead cells was calculated for each sample. The ratio of each drug-sensitized
sample was then divided by the ratio of corresponding control sample to obtain the percentage
difference  between  the  drug-sensitized  samples  and  the  control  sample.  The  smaller  the
percentage, the bigger effect the drug had on the cell line in question.
4.4. In silico mutational analysis
Frequency  of point  mutations  in  the  ERBB3  gene  in  breast  cancer  tissue  samples  was
determined using the cBioPortal (Cerami et al. 2012, Gao et al. 2013). The portal contained
four distinct breast cancer datasets generated by British Columbia Cancer Research Centre, by
the Broad Institute, and by the Sanger Institute (Banerji et al. 2012, Shah et al. 2012, Stephens
et al. 2012). Additionally, a breast cancer dataset from TCGA (The Cancer Genome Atlas)
was included in the in silico mutational analysis.
COSMIC database was used to determine whether or not the cell lines used in this study
contain mutations in the ERBB3 gene (Forbes et al. 2008, Forbes et al. 2011).
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5. Results
5.1. Amount of HER-2/HER-3 dimers in breast cancer cell lines
Proximity ligation assay was used to determine the amount of HER-2/HER-3 dimers in one
gastric carcinoma cell line and in 12 breast cancer cell lines. Results are shown in figure 8.
Two (MCF-7 and MDA-MB-231) of the total 13 different cancer cell lines were known to be
HER-2 negative and they were used as negative controls in this part of the study. The results
were expected, as the negative samples had notably less dimers than most other samples.
To confirm that  the  fluorescent  dots  visualized  really  were  HER-2/HER-3  dimers,  HER-
2/HER-3 dimerization inhibitor pertuzumab was incubated 72 hours with cells, after which a
standard  proximity  ligation  assay  protocol  was  performed.  Percentages  of  dimers  in
pertuzumab sensitized samples compared to control samples are shown in figure 9. Results
show that pertuzumab has at least a moderate effect on the amount of dimers of five (BT-474,
EFM-192A, HCC1419, MDA-MB-231, and UACC-812) of the ten tested cell lines. Two cell
lines (SK-BR-3 and OE19) show a little reduction in the amount of dimers, while three cell
lines (JIMT-1, MDA-MB-453, and ZR-75-30) are unaffected.
Example PLA images of different cell lines are shown in appendix 1, figure S1. Each image
shown have been averaged from all the stack images obtained from a single field of view.
Therefore, not all dimers are visible in the images.
Figure 8. Amount of dimers per cell in different cancer cell lines.
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Figure 9. Amount of dimers in pertuzumab sensitized cells. 100% corresponds the amount of dimers in contrtol 
samples.
5.2.  Drug sensitivity in HER-2 positive cell lines
A commercial  LIVE/DEAD  Viability/Cytotoxicity  Kit  (Life  Technologies)  was  used  to
determine  the  sensitivity  of  12  breast  cancer  and  a  single  gastric  cancer  cell  lines  to
pertuzumab, trastuzumab, and the combination of these drugs. Results of the drug sensitivity
assay are shown in figure 10.
Trastuzumab alone showed a significant (<90% proportion of living cells/dead cells in a drug-
sensitized sample compared to the corresponding control sample) effect in five of the twelve
cell lines. Pertuzumab alone showed a significant effect in seven of the thirteen cell lines.
Combination of both of the above mentioned drugs showed significant effect in ten of the
thirteen cell lines. Two (MCF-7 and MDA-MB-231) of the three cell lines which did not show
significant reaction to trastuzumab, pertuzumab, or the combination of these drugs were the
negative  control  cell  lines  of  this  experiment,  and  therefore  the  observed  results  were
expected. The third line (JIMT-1) that did not show significant response to either of the drugs
has previously been shown to be trastuzumab resistant, and this experiment indicates that it is
also resistant to pertuzumab (Köninki et al. 2010). This was expected as JIMT-1 cells contain
only a few dimers as demonstrated in figure 8.
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Even though most of the results seem reasonable, a few of them are surprising. Three of the
cell lines showing high quantity of HER-2/HER-3 dimers (BT-474, ZR-75-30 and SK-BR-3)
seem  to  be  unaffected  by  pertuzumab.  Particularly  the  insensitivity  of  BT-474  cells  to
pertuzumab is surprising, as the drug significantly decreased the amount of dimers in this cell
line  (figure  9).  Additionally,  MDA-MB-361  cells  which  show  the  strongest  reaction  to
pertuzumab have relatively few dimers when compared to for example HCC1419 cells.
Example images  of  different  cell  lines  after  the  addition  of  the LIVE/DEAD reagent  are
shown in appendix 1, Figure S2.
Figure 10. Results of the drug sensitivity assay. Percentage of the proportion of living cells/dead cells in drug-
sensitized samples are shown. 100% corresponds the proportion of living cells/dead cells in contrtol samples.
The effect of both trastuzumab and pertuzumab was tested at a concentration of 20 µg/ml.
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5.3. HER-3 point mutations in breast cancer
The cBioPortal contained data from a total of 1230 breast cancer tumor samples when this in
silico study was performed. Of these samples 20 contained a nonsynonymous point mutation
in the  ERBB3  gene (1.62% of all samples). Two mutations, leading to amino acid changes
T355I and D279Y, occured in two different samples, while 16 mutations occured only in one
sample.
GISTIC 2.0 tool (Mermel et al. 2011) had been previously used to determine the amount of
HER-2 amplified samples among the TCGA samples. 119 (12.4%) of the 962 TCGA samples
were  HER-2 amplified.  The percentage  is  a  little  lower  than  expected,  but  it  still  seems
reasonable considering that the results obtained by the GISTIC tool are only putative. Four of
the HER-2 amplified samples (3.36% of all HER-2 amplified samples) and 12 of the non-
HER-2  amplified  samples  (1.42%  of  all  non-HER-2  amplified  samples)  contained
nonsynonymous point mutations in the ERBB3 gene.
According to the COSMIC database, none of the studied cell lines contain point mutations in
HER-3. SK-BR-3 cell line is not listed in the COSMIC database, but according to the CCLE
these cells contain a nonsynonymous point mutation, leading to amino acid change E952Q in
the  ERBB3 gene.  The  mutation  is  located  in  the  kinase  domain  of  HER-3  and it  is  not
identified as a hot spot mutation
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6. Discussion
6.1. Proximity ligation assay
Proximity ligation assay can be considered to be a rather reliable method in the quantification
of HER-2/HER-3 dimers. As expected, the amount of dimers in HER-2 negative cell lines are
considerably smaller than in HER-2 positive cell lines, and addition of pertuzumab decreases
the amount of dimers in most cell  lines.  Additionally,  negative control samples (only one
primary antibody used) show hardly any dimers, whereas the sample in which two anti-HER-
2 antibodies were used shows signal so strong that it is impossible to calculate single dots.
Flow  cytometry  results  (table  1)  obtained  by  Satu  Luhtala  (Cancer  Biology  Group,
BioMediTech, University of Tampere, Finland) correlate well with proximity ligation assay
results presented earlier (figure 8 and figure 9), further confirming the accuracy of PLA. Cell
lines  which  have only few dimers  (JIMT-1 and MDA-MB-231) show smaller  fluorescent
readings in HER-2 and especially in HER-3 when compared to other cell lines. HER-3 seems
to be the limiting factor of dimer formation as the fluorescent reading of HER-3 is much
lower than the reading of HER-2. Different antibodies for HER-2 and HER-3, on the other
hand,  were  naturally  used,  and  thus  smaller  fluorescence  values  of  HER-3  does  not
necessarily mean that significantly fewer HER-3 receptors are present in cells. Additionally,
HER-2 fluorescence values were measured from saponin-permeabilized cells while the HER-
3 fluorescence values were measured from non-permeabilized cells.
Table  1.  Flow cytometry  results.  Fluorescent  values  measured  by the  BD Accuri  C6  flow cytometer  (BD
Biosciences, San Jose, CA, USA) are shown. The total amount of receptors cannot be deducted from the results.
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Cell line HER-3 fluorescence HER-2 fluorescence
BT-474 292 110 8 236 960
EFM-192A - 7 288 670
HCC1419 178 540 10 284 300
JIMT-1 43 650 1 099 780
MCF-7 - 322 210
MDA-MB-231 27 150 170 200
MDA-MB-361 - 2 128 850
MDA-MB-453 170 920 1 490 260
OE19 - 6 679 420
SK-BR-3 192 130 3 964 280
UACC-812 - 9 489 330
UACC-893 - 11 913 480
Even though most of the PLA results seem reasonable, some of them are surprising. First, two
of the cell lines having many dimers (MDA-MB-453 and ZR-75-30) seem to be unaffected by
pertuzumab.  Second,  MDA-MB-231 cell  lines  with very few dimers  seem to  be strongly
affected by pertuzumab. In this case, however, the percentage in the figure 9 is misleading.
This is due to the fact that in a sample with few dimers, a small decrease in the amount of
dimers  can  lead  to  large  decrease  in  percentage.  In  the  case  of  MDA-MB-231  cells  the
average amount  of dimers  per  cell  decreased only by one,  which corresponds 40 percent
decrease.
Even though PLA is an easy technique to perform, the image analysis proved to be relatively
difficult: choosing the right threshold values for the images, defining the size and shape of a
single dimer, and choosing the optimum distance between the stack images were no simple
tasks. The diameter of a single dimer varied a lot, from 0,5 µm to 1,5 µm, and this led to
problems when choosing the image analysis settings.  Additionally, when cell lines which
contained many dimers were analyzed, it was hard to say whether a single dot was a single
dimer or if two or more dimers had merged into a single dot. Therefore the results of cell lines
containing  a  lot  of  dimers  (HCC1419,  BT-474,  SK-BR-3,  MDA-MB-453,  UACC-893,
UACC-812, and OE19) might be too low when compared to cell lines with only a few dimers,
such as JIMT-1.
6.2. Drug sensitivity assay
The  results  obtained  from  the  drug  sensitivity  assay  are  reasonable.  Pertuzumab  and
trastuzumab  don't  seem to  have  effect  on  HER-2 negative  cell  lines,  which  is  expected.
Additionally, in the majority of the studied cell lines the combination of these two drugs had
stronger effect on cell survival than either of the drugs alone. Obtained results also correlate
well with previous studies. In a study by Barok et al.  (2011), for example, the three most
sensitive cell lines (MDA-MB-361, ZR-75-30 and BT-474) to trastuzumab were also among
the  most  sensitive  cell  lines  to  trastuzumab  in  this  study.  The  results  of  this  previous
trastuzumab drug sensitizing experiment are shown in figure 11.
Still,  even though the  results  seem to be rather  reasonable,  the method used in  the  drug
sensitivity  assay cannot  be  considered  optimal.  This  is  mainly  due  to  the  fact  that  only
relatively few dead cells were present in most samples, and the amount of living cells were
usually a few dozen times greater than the amount of dead cells. Thus, only a little change in
the amount of dead cells could have had a significant impact on the obtained results. This
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could explain the observation that  three of the cell  lines  showing high quantity of HER-
2/HER-3 dimers (BT-474, ZR-75-30 and SK-BR-3) seem to be unaffected by pertuzumab.
Figure 11. Percentage of surviving cells after 72 hours incubation with trastuzumab (10 µg/ml). Figure adapted
from Barok et al., (2011).
6.3. In silico mutation analysis
Point mutations in the ERBB3 gene are not very common in breast cancer (1.62% of the 1230
samples  studied  contained  a  nonsynonymous  missense  mutation).  Five  (E928G,  D297Y,
V104L, T355I, and G284R) of the 18 different HER-3 point mutations found in the breast
cancer samples are located in mutational hot spot sites (Jaiswal et al. 2013). One of these
mutations (V104L) is located in the subdomain I of extracellular domain, two (D297Y and
G284R) are located in the subdomain II of the extracellular domain, one (T355I) is located in
the subdomain III  of  the  extracellular  domain,  and one  (E928G) is  located in  the kinase
domain.  The fact  that majority of these mutations are  located in the extracellular  domain
indicates that most of the HER-3 point mutations affect ligand binding or dimerization. D297,
for example, is located near the dimerization arm of subdomain II and it has an important role
in  heterodimerization  (Jaiswal  et  al.  2013).  However,  further  and  more  precise  structural
analysis of the HER-3 receptor is needed to evaluate the full impact of these mutations to the
function of HER-3.
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An itriguing fact is that in breast cancers in which the ERBB2 gene is amplified, the frequency
of point mutations in the ERBB3 gene is more than two times higher than in other subtypes of
breast cancer. The total amount of mutations in all samples (20), though, is so low that it is
hard  to  conclude  if  this  is  a  signifacnt  observation  or  just  a  coincidence.  It  is  therefore
important to obtain more sequencing data from breast cancer samples in the future to better
evaluate the abundance and importance of HER-3 mutations.
The only cell line used in this study that contains a nonsynonymous point mutation in the
ERBB3 gene is SK-BR-3. This mutation leads to the amino acid change of glutamic acid
(glutamate) 952 to glutamine. The structure of these two amino acids is rather similar (figure
12), so it could be assumed that this mutation does not lead to significant changes in the three
dimensional  structure  of  the  HER-3  receptor.  Detailed  structural  analysis  is  required  to
confirm this assumption.
Figure 12. The skeletal formulas of glutamic acid and glutamine. As can be seen, the structure of these amino
acids is similar: the only difference between these molecules is that glutamic acid contains a carboxyl group in
carbon 5, while glutamine contains an amide group in carbon 5. Adapted from Reusch (2013).
The mutation  in  SK-BR-3 cells  is  located  in  the  kinase  domain  of  HER-3,  and it  might
therefore be logical to assume that it cannot affect dimerization. This is, however, not true
because the kinase domains of HER family receptors are involved in the dimerization process
(Choi et al. 2012).
In the case of SK-BR-3 cells, though, the mutation does not seem to affect the formation of
HER-2/HER-3 dimers, as the amount of dimers is high in these cells. Despite the abundance
of  HER-2/HER-3  dimers,  SK-BR-3  cells  seem  to  be  resistant  to  dimerization  inhibitor
pertuzumab, but it is not possible to say whether this is due to the mutation or not. Because
pertuzumab binds to HER-2, a point mutation in the HER-3 receptor cannot affect the binding
of this drug to its target. Thus, if the point mutation is responsible for the drug resistance, it
39
must alter the conformation of HER-3 in a way that it can dimerize with HER-2 receptors to
which pertuzumab has bound. Other possibility is that mutated HER-3 receptors can activate
the  downstream signaling  pathways,  such as  the  PI3K/Akt  pathway,  without  the  need  to
dimerize  with  HER-2.  A combination  treatment  with  both  trastuzumab  and  pertuzumab
significantly reduced the viability of SK-BR-3 cells even though neither of the drugs alone
affected these cells. This implies that if the point mutation in the HER-3 receptor of SK-BR-3
cells is responsible for the obseved insensitivity to pertuzumab, a combination treatment with
both trastruzumab and pertuzumab can help overcome this resistance.
In addition to SK-BR-3 cells, HER-2 positive cell lines BT-474 and ZR-75-30 were found to
be insensitive to pertuzumab. According to the COSMIC and CCLE databases these two cell
lines do not contain nonsynonymous point mutations in their ERBB3 genes, and therefore the
observed drug resistance does not probably stem from HER-3 mutations. It should be noted,
though, that both of these projects are unfinished, and it is possible that BT-474 and ZR-75-30
cells do contain point mutations in the  ERBB3  gene altough they are not yet listed in the
databases.
6.4. Future perspectives
The  high  abundance  of  HER-2/HER-3  heterodimers  in  HER-2  positive  cancers  is  an
important observation. As these dimers activate downstream signaling pathways that lead to
cell  proliferation  and  apoptosis  inhibition,  it  is  reasonable  to  use  them  as  drug  targets.
Furthermore, it has been proposed that HER-2 can't act alone in HER-2 positive cancer cells
or tissues, but it needs HER-3 for realizing its full signaling potential (Holbro et al. 2003).
Thus, HER-2/HER-3 heterodimers are not a minor aspect of HER-2 positive breast cancer,
and the dimers should be considered as an important target for HER-2 positive breast cancer
treatment.
Currently only one  drug,  pertuzumab,  directly  inhibiting  the  formation  of  HER-2/HER-3
dimers is under clinical testing (Harbeck N et al.  2013). Despite previous studies, clinical
trials, and the in vitro experiments performed in this thesis have shown that pertuzumab can
moderately decrease the survival of cancer cells and increase the progression-free survival,
the effect is not as good as it could be (Harbeck et al. 2013, Zagouri et al. 2013, Malenfant et
al. 2014). For example, Only 7 of the 11 HER-2 positive cancer cell lines used in this thesis
reacted significantly to pertuzumab. 10 of the 11 HER-2 positive cell lines, on the other hand,
reacted significantly to a combination treatment with both pertuzumab and trastuzumab. The
only HER-2 positive cell line not reacting to  the combination treatment was JIMT-1, a cell
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line previously shown to be resistant to HER2 targeted drug therapy (Tanner et al.  2004).
Thus, it is justified to say that pertuzumab should be used in combination with trastuzumab in
order to improve the prognosis of patients with HER-2 positive breast cancer. As pertuzumab
is the first dimerization inhibitor in clinical trials, it would also be rational to develop new,
potentially more efficient HER-2/HER-3 dimerization inhibitors in the future.
Point mutations in the HER-3 receptor could play an important role in the HER-2/HER-3
dimer formation as well as in the onset and development of several different cancer types.
One study, for example, found that HER-3 recepor mutants are able to transform colonic and
breast epithelial cells in a ligand independent manner (Jaiswal et al. 2013). HER-3 mutants
alone,  though,  are  not  enough  for  the  transformation,  and  their  oncogenic  activity  is
dependent on the kinase activity of HER-2 (Jaiswal et al. 2013). HER-3 point mutations could
also have a significant impact on the effectiveness of HER-3 receptor targeted antibody drugs
that  are  currently  under  development  (Ma el  al.  2014).  If  an  amino  acid  critical  for  the
antibody binding,  for  example,  is  mutated,  the antibody might  not  have any effect  on its
target. It would therefore be important to take these mutations into account when new drugs
are  developed.   A recent  study,  however,  suggests  that  anti-HER  antibodies  and  small
molecule inhibitors  can effectively block the signaling mediated by both nonmutated and
point mutation containing HER-3 receptors (Jaiswal et al. 2013).
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7. Conclusions
The main conclusions from this thesis are:
1. As assumed, HER-2/HER-3 heterodimers are abundant in HER-2 positive cancer cell lines,
while HER-2 negative cancer cell lines contain only few dimers.
2.  Pertuzumab,  a  drug  inhibiting  the  formation  of  HER-2/HER-3  dimers,  decreases  the
amount of dimers in most of the tested cell lines. Pertuzumab alone, though, does not have
effect on the survival of four HER-2 positive cell lines (BT-474, JIMT-1, SK-BR-3, and ZR-
75-30). Of these cell lines one, SK-BR-3, contains a nonsynonymous missense mutation in
the  ERBB3 gene. Whether or not this mutation is responsible for the observed resistance to
pertuzumab is unknown.
3.  This  thesis  further  confirms  that  a  combination  treatment  with  both  pertuzumab  and
trastuzumab has a greater negative impact on the viability of HER-2 positive cells than either
of the drugs alone.
4. Point mutations in HER-3 receptor are not very common in breast cancer, and there are
only a few recurring mutations.
5. In breast cancers in which the ERBB2 gene is amplified, the frequency of point mutations
in the ERBB3 gene is more than two times higher than in other subtypes of breast cancer. This
could mean that HER-3 point mutations play an important role in the development of HER-2
positive breast cancer.
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Appendix 1
Figure S1. Typical PLA images obtained from each of the studied cell lines. PLA signals are shown in red and 
the nuclei in blue. Each individual red dot represents one HER-2/HER-3 dimer. Middle images (HCC1419 
(control) and MDA-MB-453 (control)) in the bottom row were obtained from negative control samples. In 
negative samples, only one primary antibody (anti-HER-2) was used. The rightmost image in the bottom row 
shows an image from a sample in which two diffent anti-HER-2 antibodies, instead of a pair of anti-HER-2 Ab 
and anti-HER-3 Ab, were used.  Two different anti-HER-2 antibodies can bind to the same receptor and, as 
expected, the detected signal in the HER-2/HER-2 dimer image is considerably stronger than in any other image.
This is because two different antibodies which recognize the same protein can generate signals even if no actual 
dimers are present.
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Figure S2.  Example images from three different cell lines used in the drug sensitivity assay. Green dye stains
live cells while red dye stains dead cells. The top row shows images from control samples, the second row shows
images from trastuzumab (20 µg/ml) sensitized cells, the third row shows images from pertuzumab (20 µg/ml)
sensizited cells, and the bottom row shows images from cells sensitized with both pertuzumab and trastuzumab
(both  20  µg/ml).  MCF-7  cells  are  HER-2  negative  and  thus  they  don't  significantly  react  to  trastuzumab,
pertuzumab, or the combination of these drugs. BT-474 cells, on the other hand, are strongly HER-2 positive, but
despite this pertuzumab doesn't seem to have any effect on them. Trastuzumab, however, has notable effect on
BT-474 cells. ZR-75-30 cells were among the most drug sensitive of the tested cell lines: the control sample has
practically no dead cells, while the sample incubated with both pertuzumab and trastuzumab contains lots of red.
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